Chinese Journal of Tissue Engineering Research ›› 2010, Vol. 14 ›› Issue (13): 2403-2406.doi: 10.3969/j.issn.1673-8225.2010.13.031

Previous Articles     Next Articles

Serum cystatin C levels in patients with acute myocardial infarction following coronary artery drug stent implantation: Predictive value of cardiovascular events and target vessel lesion

Zhang Liang, Zhou Sheng-hua, Liu Qi-ming, Zhou Tao, Lin Chu-wei   

  1. Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha  410011, Hunan Province, China
  • Online:2010-03-26 Published:2010-03-26
  • Contact: Zhou Sheng-hua, Doctor, Professor, Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China
  • About author:Zhang Liang☆, Studying for doctorate, Physician, Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha 410011, Hunan Province, China iarry@sina.com

PDF

526

Abstract:

BACKGROUND: Previous studies have shown that cystatin C is a better endogenous marker of glomerular filtration rate, and is closely correlated with cardiovascular disease.
OBJECTIVE: To evaluate the prognostic value of cystatin C on cardiovascular events and target vessel lesion restenosis in patients with ST elevated acute myocardial infarction (STEAMI) treated with primary percutaneous coronary intervention.
METHODS: From October 2007 to October 2008, a total of 81 patients who underwent percutaneous coronary intervention for ST-segment elevation myocardial infarction < 12 hours from symptom onset were included at the Department of Cardiology, Second Xiangya Hospital, Central South University. According to cystatin C levels, patients were classified into 2 groups: group  A > 1.00 mg/L and group B ≤ 1.00 mg/L. The clinical data was collected during hospitalization and all patients were followed up for nearly 8 months. The relationship of cystatin C mass concentration to main adverse cardiovascular events and stent stenosis was analyzed in patients.
RESULTS AND CONCLUSION: Mean duration of clinical follow-up was 8 months. There was no significant difference in death, reinfarction, stroke or revascularization between the two groups (P > 0.05). The death rate during hospitalization was higher in the group A than in the group B (χ2=2.50, P≈0.08). There were no significant differences in death, reinfarction, stroke, revascularization and thrombosis in stent in patients of both groups (P > 0.05). A higher incidence of rehospitalization for congestive heart failure was observed in patients of group A than in group B (P < 0.05). The ratio of in-stent restenosis and target vessel new lesion was significantly higher in group A than in group B (P < 0.05). These suggested that cystatin C plasma concentrations may be associated with target vessel lesion and cardiovascular events, mainly rehospitalization for congestive heart failure, after percutaneous coronary intervention in patients with ST-elevation myocardial infarction.

CLC Number: